In this exclusive interview, Bruce Ogilvie, Executive Chairman of Alliance Entertainment (NASDAQ: AENT), outlines the company’s strategy to drive sustainable earnings growth across physical media, collectibles, and exclusive licensed content.Alliance Entertainment sits at the center of the global entertainment and collectibles ecosystem, distributing over 340,000 SKUs across vinyl, film, video games, toys, and pop culture collectibles to 35,000+ retail storefronts and 200+ e-commerce platforms. In this discussion, Ogilvie explains how Alliance’s capital-light fulfillment model, deep industry expertise, and exclusive studio relationships are creating durable competitive advantages.Key Topics Covered:• Drivers behind Alliance’s double-digit revenue growth entering fiscal 2026• Expansion of exclusive licensing agreements, including Paramount Home Entertainment• How $250M+ in trailing revenue from exclusive content builds a defensible moat• The strategic importance of Handmade by Robots, Alliance’s proprietary collectibles IP• Margin expansion driven by automation, product mix, and direct-to-consumer fulfillment• Management’s outlook for meaningful EPS growth, with earnings projected to nearly double year over yearWith physical collectibles, vinyl, and premium media formats showing renewed demand, Alliance is leveraging scale, exclusivity, and intellectual property ownership to transition toward higher-margin revenue streams while maintaining strong cash flow and balance sheet discipline.👉 Alliance Entertainment is a client of RedChip. To learn more about AENT and to read our full disclosure, visit: AENTinfo.com.#AENT #AllianceEntertainment #SmallCapStocks #InvestorInterview #StockMarketInvesting #EntertainmentStocks #MediaStocks #CollectiblesMarket #LicensingRevenue #EarningsGrowth #NASDAQStocks #ValueInvesting #GrowthStocks #WallStreet #InstitutionalInvestors #RetailInvestors #PhysicalMedia #VinylRecords #PopCultureCollectibles
In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing ~10x increase in cancer-killing metabolites while maintaining similar side effect severity versus standard capecitabine• How Processa’s approach aims to improve efficacy without increasing toxicity• Details on the formal 20-patient interim analysis evaluating safety and efficacy, expected in 2026• How this program could potentially replace current capecitabine monotherapy in certain breast cancer settings• Insights into the FDA development pathway and dose optimization ahead of a potential pivotal trial🎯 David Young brings over 40 years of experience in chemotherapy drug development, including deep expertise in 5-FU and capecitabine metabolism, which uniquely positions him to lead Processa’s clinical innovation.👉 Processa Pharmaceuticals is a client of RedChip. To learn more about PCSA and to read our full disclosure, visit: PCSAinfo.com.#ProcessaPharmaceuticals #PCSA #BiotechStocks #SmallCapStocks #Oncology #BreastCancerResearch #ClinicalTrials #Phase2Trial #CancerTherapeutics #BiotechInvesting #HealthcareStocks #NASDAQStocks #DrugDevelopment #FDAApproval #LifeSciences #GrowthStocks #InvestorInterview
In this exclusive interview, E. Will Gray II, Chairman, CEO, and Interim CFO of New Era Energy & Digital (Nasdaq: NUAI), breaks down the company’s strategy to become a critical player in AI data center infrastructure and power generation.New Era Energy & Digital is developing large scale, powered data center sites in the Permian Basin, leveraging behind the meter natural gas, future nuclear capacity, and renewable energy to meet surging demand from AI, cloud computing, and high performance computing workloads.With global spending on AI infrastructure projected to reach trillions of dollars over the next decade, NUAI is positioning itself at the intersection of energy security and digital transformation.📌 Speed to power, land availability, and cost efficiency are becoming the most critical constraints for AI data center growth. New Era Energy & Digital aims to solve these challenges with scalable, power ready sites in one of the most resource rich regions in the U.S.👉 New Era Energy & Digital is a client of RedChip. To learn more about NUAI and to read our full disclosure, visit: NUAIinfo.com.#NUAI #AIInfrastructure #DataCenters #EnergyStocks #GrowthStocks #AIInvesting #DigitalInfrastructure #InvestorInterview
In our in-depth interview, NioCorp (Nasdaq: NB) CEO Mark Smith discusses the rapidly evolving landscape for U.S. critical minerals and the company’s progress toward construction of its Elk Creek Project in Nebraska. Investors will gain insight into supply chain pressures, heavy rare earth export dynamics, and the rising strategic importance of niobium, scandium, and rare earth elements in defense and clean energy markets.🎯 Key Topics We Covered• Current global constraints impacting U.S. access to heavy rare earths• How investors should evaluate critical mineral projects using feasibility, metallurgy, permitting, and resource validation• Details on NioCorp’s collaboration with Lockheed Martin Skunk Works to advance scandium aluminum alloy technologies• Update on more than $370M raised year to date and progress with the U.S. Export Import Bank on potential project debt financing• Engineering, drilling, and site preparation milestones that position NioCorp for construction readiness📌 Why This Matters for Investors:• NioCorp is advancing one of North America’s largest critical mineral resources with all major permits secured, tier one offtake agreements in place, and growing engagement from defense and industrial end users. The company’s emphasis on feasibility-level engineering, customer-qualified metallurgy, and project financing advancement provides a clearer roadmap toward potential production.Learn more about NioCorp and the Elk Creek Project in our exclusive investor-focused conversation.NioCorp is a client of RedChip. To learn more about NB and to read our full disclosure, visit: NioCorpinfo.com.#NioCorp #NB #CriticalMinerals #RareEarths #Scandium #Niobium #DefenseIndustry #Investing #SmallCapStocks #MiningIndustry #ProjectFinancing
📌 In our exclusive interview, Nova Minerals (Nasdaq: NVA) CEO Chris Gerteisen breaks down the company’s rapid transformation into a U.S. critical minerals and gold development leader. With a $43.4 million Defense Production Act award from the U.S. Department of War, Nova is advancing toward military-grade antimony production by 2026/27 — positioning itself as the first fully integrated domestic supplier in decades.Nova’s Estelle Project in Alaska sits on a 35 km mineralized corridor hosting one of North America’s largest undeveloped gold systems, including a 5.2Moz SK-1300 pit-constrained resource. Chris discusses how the company’s latest world-class drill intercepts support strong project economics and why Nova still trades at a steep valuation discount relative to peers.👉 If you found this interview valuable, make sure to like the video, drop a comment with your thoughts or questions, and subscribe for more in-depth conversations with CEOs from emerging small-cap and microcap companies!Nova Minerals is a client of RedChip. To learn more about NVA and to read our full disclosure, visit: NVAinfo.com.#NovaMinerals #NVA #GoldStocks #CriticalMinerals #Antimony #MiningStocks #SmallCapStocks #GoldInvesting #AlaskaMining #DefenseProductionAct #USCriticalMinerals #GoldExploration
In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datasets driving new discoveries in neuropsychiatric and oncology research.• Commercial Traction: Strategic partnership with Sygnature Discovery enables global sales of BullFrog Data Networks, with up to $30M in projected revenue over 3 years.• Operational Efficiency: Lean model burning just $6M annually while advancing multiple revenue-generating programs.• Clinical Validation: Recent success in a Phase 3 oncology study with Eleison Pharmaceuticals demonstrates the power of BullFrog AI’s technology in optimizing clinical trials.• bfPREP™ Launch: New data preparation module accelerates clinical trial readiness by transforming unstructured data into AI-ready formats in days.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bullfrog AI is a client of RedChip. To learn more about BFRG and to read our full disclosure, visit: BFRGinfo.com.#BFRG #BiotechStocks #AI #DrugDiscovery #ClinicalTrials #Investing #HealthcareInnovation #SmallCapStocks #AIinBiotech
Jackpot Digital (OTCQB: JPOTF | TSXV: JJ) CEO Jake Kalpakian discusses how the company’s flagship Jackpot Blitz® platform is redefining casino poker economics through automation, recurring revenue, and global expansion.💡 Jackpot Digital represents an emerging opportunity at the intersection of technology, automation, and gaming, offering exposure to a rapidly growing segment of the global casino market.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Jackpot Digital is a client of RedChip. To learn more about JPOTF and to read our full disclosure, visit: JPOTFinfo.com.#JPOTF #JackpotDigital #SmallCapStocks #GamingStocks #CasinoTechnology #InvestorUpdate #ETG #DigitalGaming #RecurringRevenue #PokerTechnology
🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.✅ Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.✅ CNTB’s strong cash position ($71.8M) and runway into 2027, fully funding its U.S.-focused clinical milestones.✅ How its proven management team — responsible for bringing 16 drugs to FDA approval — is positioning the company for long-term growth.🎬 Watch now to learn why Connect Biopharma could be one of the most compelling small-cap biotech opportunities heading into 2026.Connect Biopharma is a client of RedChip. To learn more about CNTB and to read our full disclosure, visit: CNTBinfo.com.#CNTB #BiotechStocks #SmallCapStocks #AsthmaTreatment #COPD #HealthcareInnovation #Investing #BiotechInvesting #ClinicalTrials #NASDAQ
📊 FatPipe Networks (Nasdaq: FATN) — a pioneer in mission-critical networking and cybersecurity — is driving strong profitability and growth in the multi-billion-dollar SD-WAN and SASE markets.In this exclusive interview, Ragula Bhaskar, PhD, Co-Founder and CEO of FatPipe, discusses:✅ The company’s patented technology and 13 foundational networking patents✅ FatPipe’s 90%+ gross margins and subscription-based model with 36–60 month contracts✅ Channel-first sales strategy through 100+ reseller partners worldwide✅ FY25 financial highlights — $16.3M revenue and $2.0M net income (12.3% margin)✅ Expansion into Southeast Asia and Mexico amid rapid SD-WAN market growth (18.5% CAGR through 2030)💬 “We invented the space, we deliver the best support, and we’re scaling efficiently to grow top and bottom lines,” says Dr. Bhaskar.💡 Why Investors Should Watch:FatPipe operates at the intersection of four large and fast-growing markets — SD-WAN, Cybersecurity, Secure Access Service Edge (SASE), and Network Monitoring — expected to exceed $49B by 2030. The company’s strong IP moat, recurring revenue model, and capital efficiency position it as a rare “Rule of 40” small-cap software company.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!FatPipe is a client of RedChip. To learn more about FATN and to read our full disclosure, visit: FATNinfo.com.#FATN #SmallCapStocks #Cybersecurity #SDWAN #TechInvesting #Networking #InvestorRelations #SoftwareStocks #Profitability #FinancialNews
💡 60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoff Dow discusses the company’s mission to tackle infectious diseases with unmet medical needs — and how its FDA-approved malaria drug ARAKODA® (tafenoquine) could soon transform treatment for babesiosis, a growing tick-borne disease with no approved therapies.🚀 Key Highlights:• FDA Breakthrough Therapy Designation request submitted for tafenoquine in babesiosis (Oct 2025)• First patient cured of relapsing babesiosis using tafenoquine-based regimen• Three clinical trials underway, with data expected in 2026 to support a supplementary NDA• $245M peak U.S. market potential and ~$1.1B cumulative revenue opportunity through 2035• Commercial launch underway for ARAKODA® in malaria prevention as travel rebounds📈 Why This Matters for Investors:60 Degrees Pharmaceuticals is one of the smallest Nasdaq-listed biotechs with an FDA-approved product — and it’s pursuing a capital-efficient expansion into a large, underserved infectious disease market. With strong early efficacy signals, a clear regulatory roadmap, and increasing awareness of babesiosis nationwide, SXTP offers investors exposure to a high-upside, low-cost clinical advancement story.🧬 About the Company:60 Degrees Pharmaceuticals (Nasdaq: SXTP) develops and commercializes therapeutics for vector-borne diseases. Its lead product, ARAKODA®, is FDA-approved for malaria prevention and is being advanced into new indications including babesiosis.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!60 Degrees Pharmaceuticals is a client of RedChip. To learn more about SXTP and to read our full disclosure, visit: SXTPinfo.com.#SXTP #BiotechStocks #FDAApproval #PharmaInvesting #MicroCapStocks #InfectiousDiseases #Babesiosis #MalariaPrevention #HealthcareInnovation #Investors
🔋 Bimergen Energy (OTCQB: BESS) is emerging as a major player in the booming U.S. battery energy storage sector—and CFO Bob Brilon shares how the company is executing on a 2.0 GW pipeline backed by $250 million in equity commitments.With 2GW of BESS assets and a capital-efficient model designed to avoid shareholder dilution, Bimergen is positioned to become a cornerstone in the next generation of U.S. energy infrastructure.🗓️ Construction begins late 2025, operations expected in 2026.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bimergen Energy is a client of RedChip. To learn more about BESS and to read our full disclosure, visit: Bimergeninfo.com.#BESS #BatteryStorage #MicroCapStocks #EnergyStorage #AIInfrastructure #CleanEnergy #Bimergen #Investing #StockMarket #EnergyTransition
Mark White, CEO of Nexalin Technology (Nasdaq: NXL), joins us to discuss how Nexalin aims to simplify and make mental health care more accessible with its at-home “Halo” headset and a digital, physician-monitored model. We cover the latest peer-reviewed study results referenced by the company, the plan for U.S. and international pathways, and what investors should watch next.🎯 What you’ll learn• Nexalin’s vision for easy, drug-free, non-invasive support delivered at home• How the “Halo” headset fits into a virtual care workflow (physician-monitored)• Key takeaways from the company-referenced, peer-reviewed Alzheimer’s study• Commercial model: device + subscription (“razor/razor-blade” economics)• Near-term focus areas: mood/anxiety/sleep, TBI/PTSD, and early dementia• How management thinks about FDA strategy and global expansion🧠 Study reference (as discussed)• Nexalin references a peer-reviewed publication reporting statistically significant cognitive improvements and fMRI-observed connectivity changes in a mild Alzheimer’s cohort using a 40-Hz, 15 mA protocol, with no adverse events reported during the treatment period. 💼 Business model• Clinical setting: device placement with physicians; recurring revenue via single-use disposables/treatments• At-home: headset prescribed/ordered by a physician; subscription to access and remote monitoring via app/cloud• Goal: scale through a digital ecosystem that integrates diagnosis, treatment access, and physician oversight🔎 For investors• Thesis: simplified access, physician-monitored use at home, and recurring revenue economics could unlock a capital-efficient growth path if regulatory and clinical milestones are achieved.• Watchlist catalysts: additional study readouts, regulatory interactions/decisions, progress on U.S. pathway, international indication expansions, commercial pilots/rollouts, and updates on subscription adoption and reimbursement discussions.🔔 Drop your questions for Mark in the comments for future Q&A!Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Nexalin is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: NXLinfo.com.#Nexalin #NXL #MedTech #DigitalHealth #BrainHealth #Investing #Neurotechnology #Alzheimers #MentalHealth #AtHomeCare
Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefiningoncology drug development through artificial intelligence. Its proprietary RADR® platform leveragesover 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patienttargeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC innever-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressiveB-cell lymphomas. The company also advances CNS oncology programs via its subsidiary StarlightTherapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with globalpartners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanningJohns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value throughprecision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit LTRNinfo.com to learn more.
Foremost Clean Energy (Nasdaq: FMST) is a rapidly growing North American uranium exploration holding an option to earn up to a 70% interest in 10 underexplored properties from Denison Mines. The portfolio spans over 330,000 acres within a prospective area of the Athabasca Basin surrounded by high-grade deposits. Driven by the resurgent Nuclear Renaissance, Foremost is dedicated to realizing the full potential of its projects, actively exploring in collaboration with Denison. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/fmst to learn more.
Phoenix Motor (OTC: PEVMD) is a pioneer and emerging leader in the electric vehicle (“EV”) industry, designing, building, and integrating electric drive systems and manufacturing heavy-duty transit buses and medium- and light- duty commercial EVs. Phoenix operates two primary brands, PhoenixEV, focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school buses and delivery trucks, among others) and EdisonFuture, which intends to serve international markets, particularly Latin America and Caribbeans region.Phoenix is capitalizing on a robust market opportunity backed by significant federal and state regulatory mandates. With a commanding market share in the transit bus segment and a strategic presence in medium-duty vehicles, Phoenix has established a competitive edge through superior product quality and total cost of ownership. The Company has a base of high-profile customers and boasts a strong order backlog, evidencing substantial market demand, with contracted orders and letters of intent for approximately 250+ units representing $200M in potential revenue. Learn more at phoenixev.ai.PhoenixEV is a client of RedChip. Visit www.redchip.com/stocks/PEVMD to learn more.
60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.60 Degrees Pharmaceuticals is a client of RedChip. Visit www.redchip.com/stocks/SXTP to learn more.
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more.
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.Calidi Biotherapeutics is a client of RedChip. Visit www.redchip.com/stocks/cldi to learn more.
Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in never-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressive B-cell lymphomas. The company also advances CNS oncology programs via its subsidiary Starlight Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global partners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanning Johns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value through precision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit RedChip.com to learn more.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is strategically prioritizing metastatic breast cancer, where (Z)-endoxifen has shown encouraging clinical activity, favorable tolerability, and potential to address endocrine resistance through dual targeting of ERα and PKCβ1. With multiple Phase 2 trials completed, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Atossa Therapeutics is a client of RedChip. Visit www.redchip.com/stocks/atos to learn more.